Related Experiment Video
Updated: Aug 6, 2026
02:28
Measuring Psoriasis Severity at Home
Published on: March 1, 2024
Adalimumab: in psoriatic arthritis
1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz
Drugs
|August 16, 2006
Summary
Adalimumab significantly improved arthritis and skin symptoms in psoriatic arthritis patients. This tumour necrosis factor antagonist demonstrated efficacy and tolerability in clinical trials, offering a new treatment option.
Area of Science:
- Immunology
- Rheumatology
- Dermatology
Background:
- Psoriatic arthritis (PsA) is a chronic inflammatory condition.
- Tumour necrosis factor (TNF) antagonists are established treatments for rheumatoid arthritis.
- Efficacy of adalimumab in PsA requires further investigation.
Purpose of the Study:
- To evaluate the efficacy and safety of adalimumab in adult patients with psoriatic arthritis.
- To assess adalimumab's impact on joint and skin manifestations of PsA.
Main Methods:
- Phase III trials (ADEPT trial and a smaller study) involving adult PsA patients.
- Adalimumab (40 mg subcutaneously every other week) versus placebo.
- Assessment using American College of Rheumatology (ACR) response criteria and Psoriasis Area and Severity Index (PASI).
- Radiographic assessment using modified total Sharp score.
Main Results:
- Adalimumab showed significantly greater ACR20, ACR50, and ACR70 responses compared to placebo (p < 0.001 in ADEPT trial).
- Adalimumab treatment prevented radiographic progression of joint damage at 24 weeks in the ADEPT trial.
- Significant improvement in psoriasis symptoms (PASI responses) observed with adalimumab (e.g., PASI50 rate 75% vs 12% at 24 weeks; p < 0.001).
Conclusions:
- Adalimumab is effective in treating both the arthritis and skin manifestations of psoriatic arthritis.
- Adalimumab demonstrated a favorable safety profile, similar to its use in rheumatoid arthritis.
- Adalimumab offers a valuable therapeutic option for patients with psoriatic arthritis inadequately responding to conventional therapies.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...